Tag: Prescription Drugs
One in Five Seniors Report Cost-Related Medication Nonadherence
Most respondents indicated a desire for use of a real-time benefit tool, with concern reported regarding inaccurate prices
Brepocitinib Beneficial for Moderate-to-Severe Psoriatic Arthritis
Significantly greater ACR20 response rates seen at week 16 for 30 and 60 mg QD versus placebo; response maintained or improved at 52 weeks
Peresolimab Found to Be Efficacious for Rheumatoid Arthritis
Change from baseline in Disease Activity Score for 28 joints based on the C-reactive protein level was significantly greater for 700 mg peresolimab versus placebo at week 12
Colchicine Price Increase Tied to Poorer Gout Control Over a Decade
Simultaneously, sustained decrease in colchicine use, increased use of other medications for gout, and greater health care utilization seen
Addition of GLP1-RA Tied to Lower MACE, Heart Failure Risk in Those With Diabetes
Findings seen for people with diabetes receiving metformin, sulfonylurea, or insulin alone or in combination
FDA Panel Recommends Approval of First Nasal Spray to Combat Severe Allergic Reactions
Research included a survey showing that people would be likely to use the spray 18 minutes earlier than an injectable medication
FDA Approves First Drug Meant to Ease Alzheimer Disease-Linked Agitation
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo
Dupilumab Beneficial for Adults With Prurigo Nodularis
All primary and key secondary end points met in two phase 3 trials of adults with PN with ≥20 nodules
Pharmacologic Therapies Effective for Excessive Daytime Sleepiness
Solriamfetol, armodafinil-modafinil, and pitolisant reduce daytime sleepiness, with solriamfetol likely superior
DEA Extends Telemedicine for Prescribing Controlled Meds as Pandemic Measures End
Extension through Nov. 11, 2023, gives DEA and HHS a chance to consider revisions and public comments regarding proposals offered March 1
